BIOAGE LABS, INC. Long-Term Debt
BIOAGE LABS, INC. (BIOA) had Long-Term Debt of $0 as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-03-24
- 2025-12-31: Long-term Debt, Excluding Current Maturities $0.00.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $0.00.
- 2025-06-30: Long-term Debt, Excluding Current Maturities $0.00.
- 2025-03-31: Long-term Debt, Excluding Current Maturities $1.06M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-24 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.06M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $2.50M 10-K · filed 2026-03-24 |
| 2024-09-30 | $3.94M 10-Q · filed 2024-11-07 |
| 2023-12-31 | $8.20M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |